Viatris’ Revenue Breakdown by Segment (2020-2022)

This statistic highlights Viatris’ Revenue by Segment, split across Developed markets, Emerging Markets, Greater China and JANZ, reported on a quarterly basis from Q1 2020 onwards.

The company reports its segment information based on markets and geography. The company has four reportable segments. Such segmentation reflects Viatris’ aim to bring its diverse portfolio of branded biosimilars and generics, and generic products to market customers. The company’s Developed Markets segment operates mainly in Europe and North America. Emerging Markets cover operations in emerging economies like Asian countries, the Middle East, Africa, Eastern Europe, and South & Central America. Greater China includes—China, Taiwan, and Hong Kong. The final segment JANZ stands abbreviated for Viatris’ operations in Japan, Australia, and New Zealand.

Viatris’ Revenue by Segment

(All figures are in millions, except percentages)

The highest total revenue was grossed in Q2 2021 with $4561.7 million. It decreased by 0.9% in the latest quarter to $4520.5 million. The YoY growth from Q3 2020 to 2021 was 53.34%.

Developed markets: This segment’s operations are spread out in Europe and North America and it is one of the largest suppliers of prescription medicines in the US. Developed markets segment consistently contributes the maximum revenue. The highest revenue contributed was $2655.9 million in Q3 2021. It occupied a major 58.75% of the quarterly total. The YoY growth from Q3 2020 to 2021 was 22.78% and the QoQ growth from Q2 2021 to Q3 2021 was 0.59%. Such growth was due to the net sales from their Upjohn Business and sales from new products, however, this growth was partly offset by the lowered prices in Europe and North America. 

Emerging markets: This segment spans countries with emerging economies and developing markets. It also includes Viatris’ anti-retroviral franchise. Emerging markets is the second-highest revenue contributing segment. It grossed $792.5 million in Q3 2021. The contribution isn’t consistent through the quarters as there was a QoQ decline of 8.9% from Q2 2021 to Q3 2021. However, YoY growth (Q3 2020 to 2021) was a positive 68.26%. This growth was a result of the net sales from the Upjohn Business and the sale of products related to COVID-19 in India, though, the competitive market conditions did partly offset their growth.

Greater China: Following in line, is this segment that operates in Taiwan, China, and Hong Kong. The revenue in Q3 2020 was $31.5 million which increased to $566.8 million in Q3 2021, marking a massive YoY growth of 1699.37%. Greater China occupied 12.54% of the revenue total in Q3 2021. The growth was because of the net sales from their very impactful Upjohn business which has overall influenced most segments.

JANZ: In Q3 2020, this segment contributed $282.4 million which was almost 9 times the revenue contributed by Greater China during the same period. However, in the passing quarters, China’s growth multiplied faster. JANZ’s highest revenue earned was $505.3 million in the latest quarter—occupying 11.18% of the quarterly total. The increase in revenue could be attributed to higher net sales and great volumes of products sold in Japan in 2021.

About Viatris, Inc.:

This global healthcare company was formed in November 2020 through the combination of Upjohn Business and Mylan. Their objective is to provide more accessible, better-quality, and more affordable medicines to patients globally. Viatris amalgamates the industry’s best regulatory, legal, research & development, commercial, and medical expertise. Their geographical reach is expansive as they cater to patients in more than 165 countries and regions of the world. Since November 2020, Viatris  common stock has been listed on the NASDAQ, under the ticker symbol ‘VTRS’.

Did you like Viatris’ Revenue by Segment statistic?

Access more such key performance indicator (KPI) data points, on thousands of US stocks, with Business Quant.

You can get started here.